Table 2. Glioma risk and rs78378222 stratified by morphology type: IDH1 mutation, EGFR amplification, CDKN2A-p16-INKa homozygous deletion, 9p and 10q loss, 1p-19q co-deletion status in the French case–control series.
| Non-GBM | GBM | |||||||
|---|---|---|---|---|---|---|---|---|
|
Tumour alteration |
N |
OR |
95% CI |
P-value |
N |
OR |
95% CI |
P-value |
|
IDH1+ |
272 |
3.0 |
1.6–5.6 |
5.0 × 10−4 |
24 |
7.8 |
2.2–27.3 |
2.0 × 10−4 |
|
IDH1− |
204 |
1.4 |
0.5–3.5 |
0.52 |
238 |
2.6 |
1.3–5.3 |
4.7 × 10−3 |
|
EGFR amplified |
35 |
1.6 |
0.2–12.0 |
0.65 |
81 |
1.4 |
0.3–5.8 |
0.66 |
|
EGFR nonamplified |
438 |
2.5 |
1.4–4.4 |
1.5 × 10−3 |
185 |
3.8 |
1.9–7.4 |
4.1 × 10−5 |
| p16 Deleted |
73 |
3.2 |
1.1–9.1 |
0.03 |
97 |
3.6 |
1.5–8.8 |
2.9 × 10−3 |
| p16 Nondeleted |
393 |
2.2 |
1.2–4.0 |
0.01 |
164 |
2.8 |
1.3–6.1 |
8.0 × 10−3 |
| 9p Deleted |
140 |
2.0 |
0.8–5.2 |
0.14 |
128 |
3.2 |
1.4–7.3 |
4.7 × 10−3 |
| 9p Nondeleted |
320 |
2.5 |
1.3–4.7 |
3.8 × 10−3 |
135 |
3.0 |
1.3–6.9 |
7.3 × 10−3 |
| 10q Deleted |
140 |
2.4 |
1.0–5.9 |
0.04 |
203 |
2.0 |
0.9–4.5 |
0.1 |
| 10q Nondeleted |
316 |
2.3 |
1.2–4.5 |
9.0 × 10−3 |
62 |
6.9 |
2.9–16.3 |
3.4 × 10−7 |
| 1p-19q Codeleted |
146 |
1.9 |
0.7–5.0 |
0.17 |
28 |
NA |
NA |
0.47 |
| 1p-19q Noncodeleted | 316 | 2.7 | 1.5–5.0 | 1.1 × 10−3 | 235 | 3.4 | 1.8–6.5 | 1.0 × 10−4 |
Abbreviations: CI=confidence interval; GBM=glioblastoma multiforme; OR=odds ratio.The analysis is based on directly genotyped data for 739 cases and 1,827 controls. Per allele odds ratios are shown with the risk allele for all tests being the C-allele with the reference being AA homozygotes.